说说你对这篇新闻的看_老虎社区_美港股上老虎

tin13
2020-08-17

说说你对这篇新闻的看法...

CureVac aims to make reasonable profit on COVID-19 vaccine

Ruling out selling its mRNA-based COVID-19 vaccine at cost, if approved, fresh IPO CureVac (NASDAQ:C

CureVac aims to make reasonable profit on COVID-19 vaccine

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":970935483,"tweetId":"970935483","gmtCreate":1597629134742,"gmtModify":1704216076615,"author":{"id":3558559727742226,"idStr":"3558559727742226","authorId":3558559727742226,"authorIdStr":"3558559727742226","name":"tin13","avatar":"https://static.tigerbbs.com/259a99455556292cf7e7a111521464f4","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>说说你对这篇新闻的看法...</p></body></html>","htmlText":"<html><head></head><body><p>说说你对这篇新闻的看法...</p></body></html>","text":"说说你对这篇新闻的看法...","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/970935483","repostId":2060617053,"repostType":2,"repost":{"id":"2060617053","kind":"news","pubTimestamp":1597618697,"share":"https://www.laohu8.com/m/news/2060617053?lang=&edition=full","pubTime":"2020-08-17 06:58","market":"us","language":"en","title":"CureVac aims to make reasonable profit on COVID-19 vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2060617053","media":"Douglas W. House","summary":"Ruling out selling its mRNA-based COVID-19 vaccine at cost, if approved, fresh IPO CureVac (NASDAQ:C","content":"<html><body><div><div>\n<p>Ruling out selling its mRNA-based COVID-19 vaccine at cost, if approved, fresh IPO CureVac <span>(NASDAQ:CVAC)</span> says it plans on earning an \"ethical\" profit margin based on a competitive price.</p>\n<p>CFO Pierre Kemula declined to disclose what the expected margin will be but said the unit price will be dose-dependent not cost-related.</p>\n<p>Rival COVID-19 vaccine developers AstraZeneca <span>(NYSE:AZN)</span> and the University of Oxford have floated $3 - 4 per dose for their offering while Johnson &amp; Johnson's <span>(NYSE:JNJ)</span> will be $10 per dose, reflecting their previously stated commitment not to profit from their respective vaccines during the pandemic. Fellow mRNA vaccine developer Moderna <span>(NASDAQ:MRNA)</span> has priced some of its shots at $74 per course.</p>\n<p>Talks between the EU and company for a committed supply of product are in process.</p>\n<p>Earlier this year, the German government invested €300M in the company, representing a 23% stake, aimed at blocking any foreign takeover attempt.</p>\n<p>The company is working with Tesla Grohmann Automation, a subsidiary of the electric car maker, to develop RNA printers to help manufacture the vaccine. At present, there are eight prototypes, each capable of making 0.5 gm per week.</p>\n</div><div><p><b>Click to subscribe to real-time analytics on CVAC</b></p></div><div><p>Now read: <b>Retirement: Where You Could Invest Your Cash Today »</b></p></div></div></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CureVac aims to make reasonable profit on COVID-19 vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCureVac aims to make reasonable profit on COVID-19 vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-08-17 06:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3606046-curevac-aims-to-make-reasonable-profit-on-covidminus-19-vaccine><strong>Douglas W. House</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ruling out selling its mRNA-based COVID-19 vaccine at cost, if approved, fresh IPO CureVac (NASDAQ:CVAC) says it plans on earning an \"ethical\" profit margin based on a competitive price.\nCFO Pierre ...</p>\n\n<a href=\"https://seekingalpha.com/news/3606046-curevac-aims-to-make-reasonable-profit-on-covidminus-19-vaccine\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","JNJ":"强生","CVAC":"CureVac B.V.","AZN":"阿斯利康"},"source_url":"https://seekingalpha.com/news/3606046-curevac-aims-to-make-reasonable-profit-on-covidminus-19-vaccine","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2060617053","content_text":"Ruling out selling its mRNA-based COVID-19 vaccine at cost, if approved, fresh IPO CureVac (NASDAQ:CVAC) says it plans on earning an \"ethical\" profit margin based on a competitive price.\nCFO Pierre Kemula declined to disclose what the expected margin will be but said the unit price will be dose-dependent not cost-related.\nRival COVID-19 vaccine developers AstraZeneca (NYSE:AZN) and the University of Oxford have floated $3 - 4 per dose for their offering while Johnson & Johnson's (NYSE:JNJ) will be $10 per dose, reflecting their previously stated commitment not to profit from their respective vaccines during the pandemic. Fellow mRNA vaccine developer Moderna (NASDAQ:MRNA) has priced some of its shots at $74 per course.\nTalks between the EU and company for a committed supply of product are in process.\nEarlier this year, the German government invested €300M in the company, representing a 23% stake, aimed at blocking any foreign takeover attempt.\nThe company is working with Tesla Grohmann Automation, a subsidiary of the electric car maker, to develop RNA printers to help manufacture the vaccine. At present, there are eight prototypes, each capable of making 0.5 gm per week.\nClick to subscribe to real-time analytics on CVACNow read: Retirement: Where You Could Invest Your Cash Today »","news_type":1},"isVote":1,"tweetType":1,"viewCount":941,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":25,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}